Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
ACE2 pathways in ACE inhibitor action warrant targeted trials; leaves open any change to current HF or CKD prescribing.
Inhibition of the angiotensin-converting enzyme (ACE) protects against the progression of several cardiovascular diseases. Recent evidence suggests that some of the beneficial effects of ACE inhibitors can be attributed to the activation of a distinct ACE signaling cascade rather than to the changes in angiotensin II and bradykinin levels. Moreover, at least one other ACE homolog (ACE2) plays a significant role in the regulation of heart and kidney function.
No takes yet. Share an insight, caveat, or question.
Fleming et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: